Literature DB >> 32101695

Androgen deprivation therapy: indications, methods of utilization, side effects and their management.

Diana E Magee1, Rajiv K Singal.   

Abstract

Our objective is to provide an up-to-date summary of current literature on the indications for androgen deprivation therapy (ADT), ways in which ADT is used, and the main side effects associated with its use. MEDLINE (Pubmed) was searched for relevant papers published from database inception to May 1, 2019 for studies evaluating the use of ADT and its associated adverse events. ADT is a mainstay in the treatment of prostate cancer and is used throughout the disease course. While predominantly used in the metastatic setting, ADT has a role in the treatment of localized disease and in the management of recurrent cancer. Intermittent ADT has an application for a certain subset of men with recurrent and metastatic disease who have significant side effects. Associated side effects of ADT are wide ranging and include osteoporosis with an associated increased fracture risk, elevated rates of diabetes, metabolic syndrome, cardiovascular risk, sexual dysfunction and hot flashes. As ADT has a variety of associated side effects, care for men receiving ADT is best managed in a multidisciplinary setting with active participation between the treating physician (urologist, radiation oncologist) and their primary care physician.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32101695

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  7 in total

1.  Thérapies endocriniennes contre les cancers du sein et de la prostate: Éléments essentiels en première ligne.

Authors:  Geneviève Chaput; Nureen Sumar
Journal:  Can Fam Physician       Date:  2022-04       Impact factor: 3.275

2.  Endocrine therapies for breast and prostate cancers: Essentials for primary care.

Authors:  Genevieve Chaput; Nureen Sumar
Journal:  Can Fam Physician       Date:  2022-04       Impact factor: 3.275

3.  [62/m-acute lumbago and prostate-specific antigen 1430 ng/ml : Preparation for the medical specialist examination: part 22].

Authors:  Miriam Hegemann
Journal:  Urologe A       Date:  2021-10-13       Impact factor: 0.639

Review 4.  Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy.

Authors:  Masaki Shiota; Leandro Blas; Masatoshi Eto
Journal:  Cancers (Basel)       Date:  2022-05-30       Impact factor: 6.575

Review 5.  Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?

Authors:  Bartosz Małkiewicz; Miłosz Knura; Małgorzata Łątkowska; Maximilian Kobylański; Krystian Nagi; Dawid Janczak; Joanna Chorbińska; Wojciech Krajewski; Jakub Karwacki; Tomasz Szydełko
Journal:  Cancers (Basel)       Date:  2022-05-08       Impact factor: 6.575

6.  Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients.

Authors:  Marieke van Son; Max Peters; Marinus Moerland; Sandrine van de Pol; Wietse Eppinga; Jan Lagendijk; Jochem van der Voort van Zyp
Journal:  Clin Transl Radiat Oncol       Date:  2020-12-11

7.  The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics.

Authors:  Feng Xiao; Jiayu Liu; Yongbo Zheng; Zhen Quan; Wei Sun; Yao Fan; Chunli Luo; Hailiang Li; Xiaohou Wu
Journal:  J Biomater Appl       Date:  2020-12-06       Impact factor: 2.646

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.